Oxford Immunotec brings $40m share sale to raise working capital
Oxford Immunotec, the UK diagnostics company focused on developing tests for underserved immune-regulated conditions, has priced a $40m capital increase to finance its ongoing product development programmes.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts